ArticleNature communications2024
Clinically used broad-spectrum antibiotics compromise inflammatory monocyte-dependent antibacterial defense in the lung.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 18 citations in OpenAlex.
- Stroke-associated pneumonia: from immunodepression to bedside management and future research directions.Neurological research and practice · 2026Review
- The Role of the Respiratory Microbiome in Pneumonia.Clinics in chest medicine · 2026Review
- Systemic corticosteroids for severe community-acquired pneumonia: a narrative review of mechanisms and critical appraisal of recent trials in ICU.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Antibiotic-induced gut microbiome remodeling reduces neuroinflammation in traumatic brain injury.Communications biology · 2026Article
- Organ cross-talk: molecular mechanisms, biological functions, and therapeutic interventions for diseases.Signal transduction and targeted therapy · 2026Review
- Fiber-deprived diet weakens lung defense against antimicrobial-resistantGut microbes reports · 2026Article
- Microbiome dysbiosis and its modulation in cancer development, prevention and therapy.Frontiers in oncology · 2026Review
- The hidden cost of antibiotics: microbial dysbiosis-induced SCFA imbalance and its underlying mechanisms.Frontiers in immunology · 2026Review
- Lung dysbiosis disrupts an FFAR2-mediated innate immune circuit againstTheranostics · 2026Article
- Omics Approaches to Unraveling the Complexity of the Gut-Lung Axis.Methods in molecular biology (Clifton, N.J.) · 2026Review
- Prospective association between the gut microbiota and incident pneumonia: a cohort study of 6419 individuals.Respiratory research · 2025Article
- Gut microbiome remodeling by antibiotics reduces neuroinflammation in traumatic brain injury.Research square · 2025Article
- Spectrum of clinically significant melanized fungi in NIH hospitalized patients and their antifungal susceptibility profiles.Medical mycology · 2025Article
- The role and mechanism of lung microbiota in coal mine dust-induced NLRP3 inflammasome upregulate and lung injury.Scientific reports · 2025Article
- Effects of Broad-Spectrum Antimicrobials on Patients with Community-Acquired Pneumonia with Low Risk for Drug-Resistant Pathogens: Historical Cohort Study in Japan.Infectious diseases and therapy · 2025Article
- Gut microbiota dysbiosis drives stroke-associated pneumonia: mechanisms and targeted therapeutic strategies.Frontiers in neuroscience · 2025Review
- Membrane-targeting antibacterial isoniazid schiff base againstFrontiers in chemistry · 2025Article
- Clinical Characteristics and Independent Risk Factors for Multidrug-ResistantInfection and drug resistance · 2025Article
- Screening of promising molecules against potential drug targets in Yersinia pestis by integrative pan and subtractive genomics, docking and simulation approach.Archives of microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 7 institutions in 1 country.
Patrick J DörnerDepartment of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Harithaa AnandakumarExperimental and Clinical Research Center, a cooperation of Charité - Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.
Ivo RöwekampDepartment of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0001-8365-2546
Facundo Fiocca VernengoDepartment of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0003-2293-5598
Belén Millet Pascual-LeoneDepartment of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0003-4287-282X
Marta KrzanowskiDepartment of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0002-5319-0982
Josua SellmaierDepartment of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID http://orcid.org/0009-0002-9373-8188
Ulrike BrüningMetabolomics Platform, Berlin Institute of Health at Charité, Berlin, Germany.ORCID http://orcid.org/0000-0003-0112-4032
Raphaela Fritsche-GuentherMetabolomics Platform, Berlin Institute of Health at Charité, Berlin, Germany.
Lennart PfannkuchDepartment of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Florian KurthDepartment of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0002-3807-473X
Miha MilekCore Unit Bioinformatics, Berlin Institute of Health at Charité, Berlin, Germany.ORCID http://orcid.org/0000-0002-0803-8439
Vanessa IgbokweDepartment of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Ulrike LöberExperimental and Clinical Research Center, a cooperation of Charité - Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.ORCID http://orcid.org/0000-0001-7468-9531
Birgitt GutbierDepartment of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Markus HolsteinDepartment of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Gitta Anne HeinzGerman Rheumatism Research Center, a Leibniz Institute, Berlin, Germany.ORCID http://orcid.org/0000-0002-9330-3689
Mir-Farzin MashreghiGerman Rheumatism Research Center, a Leibniz Institute, Berlin, Germany.ORCID http://orcid.org/0000-0002-8015-6907
Leon N SchulteDepartment of Medicine, Institute for Lung Research, Philipps University Marburg, Marburg, Germany.
Ann-Brit KlattDepartment of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Sandra CaesarDepartment of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Sandra-Maria WienholdDepartment of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0001-5655-4350
Stefan OffermannsMax-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany.ORCID http://orcid.org/0000-0001-8676-6805
Matthias MackDepartment of Nephrology, University Hospital Regensburg, Regensburg, Germany.ORCID http://orcid.org/0000-0002-3157-7262
Martin WitzenrathDepartment of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Stefan JordanInstitute of Microbiology, Infectious Diseases and Immunology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0001-9330-1715
Dieter BeuleCore Unit Bioinformatics, Berlin Institute of Health at Charité, Berlin, Germany.
Jennifer A KirwanMetabolomics Platform, Berlin Institute of Health at Charité, Berlin, Germany.
Sofia K ForslundExperimental and Clinical Research Center, a cooperation of Charité - Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.ORCID http://orcid.org/0000-0003-4285-6993
Nicola WilckExperimental and Clinical Research Center, a cooperation of Charité - Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.ORCID http://orcid.org/0000-0003-3189-5364
Hendrik BartolomaeusExperimental and Clinical Research Center, a cooperation of Charité - Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.ORCID http://orcid.org/0000-0003-4288-3828
Markus M HeimesaatInstitute of Microbiology, Infectious Diseases and Immunology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Bastian OpitzDepartment of Infectious Diseases, Respiratory Medicine and Critical Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. bastian.opitz@charite.de.ORCID http://orcid.org/0000-0003-1276-836X
Humboldt-Universität zu Berlin · DEBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DEMax Delbrück Center · DEGerman Rheumatism Research Centre · DEMax Planck Institute for Heart and Lung Research · DEPhilipps University of Marburg · DEUniversity Hospital Regensburg · DE
Funding
Deutsche Forschungsgemeinschaft (German Research Foundation) OP 86/12-1Deutsche Forschungsgemeinschaft (German Research Foundation) OP 86/13-1Deutsche Forschungsgemeinschaft (German Research Foundation) SFB 1449 B02Deutsche Forschungsgemeinschaft (German Research Foundation) SFB-TR84 A5
Abstract
Hospital-acquired pneumonia (HAP) is associated with high mortality and costs, and frequently caused by multidrug-resistant (MDR) bacteria. Although prior antimicrobial therapy is a major risk factor for HAP, the underlying mechanism remains incompletely understood. Here, we demonstrate that antibiotic therapy in hospitalized patients is associated with decreased diversity of the gut microbiome and depletion of short-chain fatty acid (SCFA) producers. Infection experiments with mice transplanted with patient fecal material reveal that these antibiotic-induced microbiota perturbations impair pulmonary defense against MDR Klebsiella pneumoniae. This is dependent on inflammatory monocytes (IMs), whose fatty acid receptor (FFAR)2/3-controlled and phagolysosome-dependent antibacterial activity is compromized in mice transplanted with antibiotic-associated patient microbiota. Collectively, we characterize how clinically relevant antibiotics affect antimicrobial defense in the context of human microbiota, and reveal a critical impairment of IM´s antimicrobial activity. Our study provides additional arguments for the rational use of antibiotics and offers mechanistic insights for the development of novel prophylactic strategies to protect high-risk patients from HAP.
Indexed as
Anti-Bacterial AgentsAnti-Infective AgentsAnimalsHumansKlebsiella pneumoniaeLungMiceMonocytesAnti-Bacterial AgentsAnti-Infective Agents
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.